DK2051987T3 - Anvendelse af cd83 i kombinationsterapier - Google Patents

Anvendelse af cd83 i kombinationsterapier Download PDF

Info

Publication number
DK2051987T3
DK2051987T3 DK07811339.6T DK07811339T DK2051987T3 DK 2051987 T3 DK2051987 T3 DK 2051987T3 DK 07811339 T DK07811339 T DK 07811339T DK 2051987 T3 DK2051987 T3 DK 2051987T3
Authority
DK
Denmark
Prior art keywords
cells
soluble
disease
administration
use according
Prior art date
Application number
DK07811339.6T
Other languages
English (en)
Inventor
Charles Nicolette
Hao Wang
Jacqueline Arp
Siobhan Ramcharran
Mirin Lorea Baroja
Zhen Zhong
Stephen Brand
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Application granted granted Critical
Publication of DK2051987T3 publication Critical patent/DK2051987T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02006—NAD(P)+ nucleosidase (3.2.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)

Claims (17)

1. Opløselig CD83 til anvendelse til forebyggelse, helbredelse eller lindring af mindst ét symptom på en sygdom eller forstyrrelse, der er forårsaget af dysfunktion eller uønsket funktion af en immunreaktion, i kombination med en første immunsuppressiv forbindelse, hvor den første immunsuppressive forbindelse er udvalgt blandt cyclosporin, tacrolimus, sirolimus og anti-CD45RB-mAb, hvor sygdommen eller forstyrrelsen er udvalgt fra gruppen, der består af en allergi; astma; afstødning af transplanteret væv; en immunreaktion mod et kronisk administreret stof; en autoimmunsygdom; og AIDS.
2. Opløselig CD83 til anvendelse ifølge krav 1, hvor den opløselige CD83 og den første immunsuppressive forbindelse er til administration i den samme formulering og ved hjælp af den samme administrationsmetode eller er til administration i forskellige formuleringer og/eller ved hjælp af forskellige administrationsmetoder.
3. Opløselig CD83 til anvendelse ifølge krav 1 eller krav 2, hvor den første immunsuppressive forbindelse er cyclosporin.
4. Opløselig CD83 til anvendelse ifølge krav 1 eller krav 2, som er til anvendelse i kombination med en anden immunsuppressiv forbindelse, hvor den første immunsuppressive forbindelse er sirolimus, og den anden immunsuppressive forbindelse er anti-CD45RB-mAb.
5. Opløselig CD83 til anvendelse ifølge krav 1 eller krav 2, som er til anvendelse i kombination med en anden immunsuppressiv forbindelse, hvor den første immunsuppressive forbindelse er tacrolimus, og den anden immunsuppressive forbindelse er mycophenolatmofetil.
6. Opløselig CD83 til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor CD83 og den første immunsuppressive forbindelse er til administration inden for tre dage fra hinanden.
7. Opløselig CD83 til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor sygdommen eller forstyrrelsen er en autoimmunsygdom.
8. Opløselig CD83 til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor CD83 administreres ved indførelse af nukleinsyre, der koder for CD83, i individet.
9. Opløselig CD83 til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor sygdommen eller forstyrrelsen er afstødning af transplanteret væv, og hvor den opløselige CD83 er til administration til en transplanteret patient sammen med det transplanterede væv og/eller til administration til den transplanterede patient efter transplantationen af vævet.
10. Opløselig CD83 til anvendelse ifølge krav 9, som er til administration sammen med et terapeutisk præparat.
11. Opløselig CD83 til anvendelse ifølge krav 9, hvor det terapeutiske præparat er et antigen, der er forbundet med det transplanterede væv.
12. Opløselig CD83 til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor sygdommen eller forstyrrelsen er afstødning af transplanteret væv, og hvor den opløselige CD83 er til administration i et væv, der skal transplanteres, efter udtagning fra en donor.
13. Kombination af opløselig CD83 og en første immunsuppressiv forbindelse til anvendelse til forebyggelse, helbredelse eller lindring af mindst ét symptom på en sygdom eller forstyrrelse, der er forårsaget af dysfunktionen eller den uønskede funktion af en immunreaktion, hvor den første immunsuppressive forbindelse er udvalgt fra gruppen, der består af cyclosporin, tacrolimus, siro limus og anti-CD45RB-mAb, hvor sygdommen eller forstyrrelsen er udvalgt fra gruppen, der består af en allergi; astma; afstødning af transplanteret væv; en immunreaktion mod et kronisk administreret stof; en autoimmunsygdom; og AIDS.
14. Opløselig CD83 til anvendelse ifølge et hvilket som helst af kravene 1 til 12 eller kombination til anvendelse ifølge krav 13, hvor hver af den opløselige CD83, den første immunsuppressive forbindelse, den anden immunsuppressive forbindelse og det terapeutiske præparat er til samtidig administration eller er til separat administration.
15. Anvendelse af en kombination af opløselig CD83 og en første immunsuppressiv forbindelse til behandling af et væv, der skal transplanteres, efter udtagning fra en donor og før transplantation, hvor den første immunsuppressive forbindelse er udvalgt fra gruppen, der består af cyclosporin, tacrolimus, sirolimus og anti-CD45RB-mAb.
16. Opløselig CD83 til anvendelse ifølge krav 1 eller kombination af opløselig CD83 og en første immunsuppressiv forbindelse til anvendelse ifølge krav 13, hvor autoimmunsygdommen er udvalgt fra gruppen, der består af myasthenia gravis, kronisk inflammatorisk tarmsygdom, ankyloserende spondylitis, systemisk lupus erythematosus, psoriasis, rheumatoid arthritis og insulinafhængig diabetes mellitus.
17. Opløselig CD83 til anvendelse ifølge krav 16 eller kombination af opløselig CD83 og en første immunsuppressiv forbindelse til anvendelse ifølge krav 16, hvor den kroniske inflammatoriske tarmsygdom er Crohns sygdom eller ulcerativ colitis.
DK07811339.6T 2006-08-18 2007-08-16 Anvendelse af cd83 i kombinationsterapier DK2051987T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83881206P 2006-08-18 2006-08-18
US92737707P 2007-05-04 2007-05-04
PCT/US2007/018048 WO2008024242A2 (en) 2006-08-18 2007-08-16 Use of cd83 in combination therapies

Publications (1)

Publication Number Publication Date
DK2051987T3 true DK2051987T3 (da) 2015-01-05

Family

ID=39107298

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07811339.6T DK2051987T3 (da) 2006-08-18 2007-08-16 Anvendelse af cd83 i kombinationsterapier

Country Status (13)

Country Link
US (4) US20140010821A1 (da)
EP (2) EP2789625B1 (da)
JP (2) JP5570808B2 (da)
KR (1) KR101521197B1 (da)
CN (2) CN101484461B (da)
AU (1) AU2007288368B2 (da)
CA (1) CA2658000C (da)
DK (1) DK2051987T3 (da)
ES (1) ES2526548T3 (da)
IL (1) IL195190A (da)
MX (1) MX2008015395A (da)
SI (1) SI2051987T1 (da)
WO (1) WO2008024242A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538787A (en) * 1994-05-16 1996-07-23 New Waste Concepts, Inc. Material and method for forming an underwater barrier layer
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN101484461B (zh) 2006-08-18 2014-09-17 阿哥斯医疗公司 Cd83在联合治疗中的用途
JP2011520959A (ja) * 2008-05-23 2011-07-21 アルゴス・セラピューティクス・インコーポレーテッド 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法
US9987354B2 (en) 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
JP6048949B2 (ja) * 2012-05-23 2016-12-21 国立大学法人 筑波大学 同種間での移植心臓、移植血管、または移植腎臓の生着を維持するために用いられる薬剤
WO2014116908A1 (en) * 2013-01-24 2014-07-31 University Of Florida Research Foundation, Incorporated Method for generation of regulatory t-cells using factors secreted by inkt cells
CN110251675A (zh) * 2013-05-03 2019-09-20 西莱克塔生物科技公司 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US5831068A (en) 1995-08-21 1998-11-03 Duke University Method to increase the density of antigen on antigen presenting cells
AU2273397A (en) 1996-02-15 1997-09-02 Immunex Corporation Methods and compositions for modulating an immune response
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CN1736483A (zh) * 1997-05-17 2006-02-22 拜奥根Idec马萨诸塞公司 应用cd40：cd154结合阻断物预防反适应性免疫应答,特别是移植物排斥反应
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
US7015204B1 (en) 1999-10-07 2006-03-21 Cornell Research Foundation, Inc. Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
MXPA03010568A (es) * 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
EP1422241A1 (en) * 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
CN101484461B (zh) 2006-08-18 2014-09-17 阿哥斯医疗公司 Cd83在联合治疗中的用途

Also Published As

Publication number Publication date
HK1130263A1 (en) 2009-12-24
EP2051987B1 (en) 2014-11-19
CA2658000C (en) 2017-02-07
KR20090041366A (ko) 2009-04-28
AU2007288368B2 (en) 2013-07-04
CN104177464A (zh) 2014-12-03
CN104177464B (zh) 2017-04-12
ES2526548T3 (es) 2015-01-13
US20230158109A1 (en) 2023-05-25
HK1204626A1 (en) 2015-11-27
US20160008440A1 (en) 2016-01-14
US20160324926A1 (en) 2016-11-10
IL195190A (en) 2016-04-21
KR101521197B1 (ko) 2015-05-18
WO2008024242A3 (en) 2008-10-23
CN101484461A (zh) 2009-07-15
JP2010501556A (ja) 2010-01-21
EP2051987A2 (en) 2009-04-29
JP2014193881A (ja) 2014-10-09
EP2789625A1 (en) 2014-10-15
AU2007288368A1 (en) 2008-02-28
JP5570808B2 (ja) 2014-08-13
HK1203078A1 (en) 2015-10-16
WO2008024242A2 (en) 2008-02-28
SI2051987T1 (sl) 2015-02-27
MX2008015395A (es) 2008-12-15
EP2789625B1 (en) 2018-06-06
IL195190A0 (en) 2009-08-03
CA2658000A1 (en) 2008-02-28
EP2051987A4 (en) 2011-08-03
CN101484461B (zh) 2014-09-17
JP5898260B2 (ja) 2016-04-06
US20140010821A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
US20230158109A1 (en) Use of cd83 in combination therapies
EP1397153B1 (en) Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
RU2535340C2 (ru) Новые растворимые полипептиды cd83, композиции и способы их применения
US9822161B2 (en) ILT3 polypeptides and uses thereof
AU2013237703B2 (en) Use of cd83 in combination therapies
HK1203078B (en) Use of soluble cd83 for perfusing a tissue for transplantation
HK1130263B (en) Use of cd83 in combination therapies
WO2009111889A1 (en) Lymphocyte control of obesity and insulin resistance
HK1204626B (en) Use of cd83 in combination therapies
Parker Reversal of overt type I diabetes in the NOD mouse through the use of combination therapy
CN103037890A (zh) 来自蜱的树突状细胞抑制蛋白